Auditor (@auditor112017) profile picture

Retired Internal Auditor (CISA), Accountant, and Info Sec Engineer. Followed biotech, pharma, banking and tech sectors for more than 25 years.

Joined October 2017
Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)
HIBSAGO should play a larger part in $IONS revenue. Per 10Q: "In October 2026, we achieved a $30 million milestone payment when the FDA approved HIBSAGO for the treatment of CHB infection. We will achieve the next payment of up to $35 million if HIBSAGO is approved in China."
1
172
$IONS is learning how to sell a new treatment for sHTG. Their sales estimate was too high for a new treatment. It is harder to change change physician behavior and patient selection. They should have learned from the slow launches from PCSK9, ATTR, and other rare diseases.
2
230
$WVE Looking forward to Wave’s 2026 Virtual Research Day Nov 4, 2026 9:30 AM EST
1
1
247
$IONS $BIIB Surprising to see Spinraza sales increased! finance.yahoo.com/markets/st…
1
5
584
$BIIB partnered Spinraza and Qalsody with $ions.
1
289
$IONS $BIIB Seems like the SMA community is looking forward to the potential approval of Salanersen (annual dosing). If approved, we could see potential increase in revenue growth. Ionis will get much better royalties. 2028 event!
250
$IONS Per BM on the recent MS webcast, the goal is to protect TRYNGOLZA franchise and he is shooting for ph3 for ION775 (siRNA) by end of 2027. Looks very optimistic! But should be interesting to see if the drug will have a 6mos or 1yr dosing.
2
160
$IONS $PRAX should have a ph3 data readout by year end or early next yr for Elsunersen. Very confusing partnership! clinicaltrials.gov/study/NCT… ir.praxismedicines.com/news-…
1
521
$IONS $PRAX Looks like Elsunersen qualifies for the Rare Pediatric Disease Priority Review Voucher (PRV).
454